Compare Estee Lauder Companies Inc (EL) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Philip Morris International Inc. — how do they compare? Estee Lauder Companies Inc trades at $87.35 (market cap $31.76B), while Philip Morris International Inc. trades at $185.78 (market cap $290.24B). The key difference: Philip Morris International Inc. is far larger — about 9.1× Estee Lauder Companies Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.16%). Which is the better fit depends on your goals.
| EL | PM | |
|---|---|---|
Market Cap | $31.76B | $290.24B |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $119.61 | $200.17 |
52-Week Low | $67.23 | $144.33 |
Enterprise Value | $37.93B | $333.36B |
Dividend Yield | 1.59% | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $87.19, down 1.31% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with a net loss of $1.13B in 2025 and negative profit margins, though recent quarters have consistently beaten EPS expectations. Analyst sentiment is divided with a Hold consensus and $91.67 price target, while institutional activity shows significant position changes including Bank of America's 950.9% stake increase in Q1 2026.
The stock presents a recovery opportunity with strong brand positioning and recent product launches like the Glimmer fragrance, but faces headwinds from declining revenues and profitability. Near-term catalysts include the upcoming Q2 2026 earnings report where EL is expected to post $0.3193 EPS. The key risk remains execution on margin improvement amid competitive pressures in the beauty sector.
Philip Morris International (PM) trades at $186.00, down 1.88% on the day, with a neutral technical signal. The stock shows strong profitability with a 25.56% net income margin and has beaten earnings estimates in two of the last three quarters. Recent news highlights a $500 million impairment charge and a lowered profit forecast due to cost pressures, though the IQOS brand was recognized as a top global brand. Analyst consensus remains bullish with a $211.17 price target.
The outlook is mixed; strong cash flow and brand strength support long-term value, but near-term headwinds from cost inflation and illicit market growth pose risks. The current valuation at a P/E of 25.57 appears fair given earnings resilience, making PM a hold for investors tolerant of sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
